Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

Overview of attention for article published in Arthritis Research & Therapy, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet
twitter: 3 X users

patent: 2 patents

Citations

dimensions_citation: 50 Dimensions

Readers on

mendeley: 92 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

ANTI-BAFF ANTIBODY MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THIS MOLECULE, METHODS…

Application EA-033604-B1

Eurasian Patent Organisation

NOVEL ANTI-BAFF ANTIBODIES

Application WO-2016039801-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.